These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 22323828)

  • 21. Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.
    Maguire AM; Bennett J; Aleman EM; Leroy BP; Aleman TS
    Mol Ther; 2021 Feb; 29(2):442-463. PubMed ID: 33278565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of Same-Eye Subretinal Sequential Readministration of
    Weed L; Ammar MJ; Zhou S; Wei Z; Serrano LW; Sun J; Lee V; Maguire AM; Bennett J; Aleman TS
    Mol Ther Methods Clin Dev; 2019 Dec; 15():133-148. PubMed ID: 31660416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection.
    Jacobson SG; Acland GM; Aguirre GD; Aleman TS; Schwartz SB; Cideciyan AV; Zeiss CJ; Komaromy AM; Kaushal S; Roman AJ; Windsor EA; Sumaroka A; Pearce-Kelling SE; Conlon TJ; Chiodo VA; Boye SL; Flotte TR; Maguire AM; Bennett J; Hauswirth WW
    Mol Ther; 2006 Jun; 13(6):1074-84. PubMed ID: 16644289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Manufacturing and regulatory strategies for clinical AAV2-hRPE65.
    Wright JF; Wellman J; High KA
    Curr Gene Ther; 2010 Oct; 10(5):341-9. PubMed ID: 20712582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene therapy for eye as regenerative medicine? Lessons from RPE65 gene therapy for Leber's Congenital Amaurosis.
    Rakoczy EP; Narfström K
    Int J Biochem Cell Biol; 2014 Nov; 56():153-7. PubMed ID: 25286304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Let There Be Light: Gene and Cell Therapy for Blindness.
    Dalkara D; Goureau O; Marazova K; Sahel JA
    Hum Gene Ther; 2016 Feb; 27(2):134-47. PubMed ID: 26751519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful gene therapy in older Rpe65-deficient dogs following subretinal injection of an adeno-associated vector expressing RPE65.
    Annear MJ; Mowat FM; Bartoe JT; Querubin J; Azam SA; Basche M; Curran PG; Smith AJ; Bainbridge JW; Ali RR; Petersen-Jones SM
    Hum Gene Ther; 2013 Oct; 24(10):883-93. PubMed ID: 24028205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene therapy restores vision in a canine model of childhood blindness.
    Acland GM; Aguirre GD; Ray J; Zhang Q; Aleman TS; Cideciyan AV; Pearce-Kelling SE; Anand V; Zeng Y; Maguire AM; Jacobson SG; Hauswirth WW; Bennett J
    Nat Genet; 2001 May; 28(1):92-5. PubMed ID: 11326284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The consortium project to treat RPE65 deficiency in humans.
    Hauswirth WW
    Retina; 2005 Dec; 25(8 Suppl):S60. PubMed ID: 16374340
    [No Abstract]   [Full Text] [Related]  

  • 30. Using the NAFX to measure the effectiveness over time of gene therapy in canine LCA.
    Jacobs JB; Dell'Osso LF; Wang ZI; Acland GM; Bennett J
    Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4685-92. PubMed ID: 19458334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function.
    Annear MJ; Bartoe JT; Barker SE; Smith AJ; Curran PG; Bainbridge JW; Ali RR; Petersen-Jones SM
    Gene Ther; 2011 Jan; 18(1):53-61. PubMed ID: 20703309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation.
    Aguirre GK; Komáromy AM; Cideciyan AV; Brainard DH; Aleman TS; Roman AJ; Avants BB; Gee JC; Korczykowski M; Hauswirth WW; Acland GM; Aguirre GD; Jacobson SG
    PLoS Med; 2007 Jun; 4(6):e230. PubMed ID: 17594175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of the Human Visual Cortex in Assessment of the Long-Term Durability of Retinal Gene Therapy in Follow-on RPE65 Clinical Trial Patients.
    Ashtari M; Nikonova ES; Marshall KA; Young GJ; Aravand P; Pan W; Ying GS; Willett AE; Mahmoudian M; Maguire AM; Bennett J
    Ophthalmology; 2017 Jun; 124(6):873-883. PubMed ID: 28237426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene therapy for Leber congenital amaurosis: advances and future directions.
    Hufnagel RB; Ahmed ZM; Corrêa ZM; Sisk RA
    Graefes Arch Clin Exp Ophthalmol; 2012 Aug; 250(8):1117-28. PubMed ID: 22644094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.
    Le Meur G; Stieger K; Smith AJ; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Péréon Y; Cherel Y; Ali RR; Hamel C; Moullier P; Rolling F
    Gene Ther; 2007 Feb; 14(4):292-303. PubMed ID: 17024105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Ocular Gene Therapy in an Italian Patient Affected by Congenital Leber Amaurosis Type 2 Treated in Both Eyes.
    Testa F; Maguire AM; Rossi S; Marshall K; Auricchio A; Melillo P; Bennett J; Simonelli F
    Adv Exp Med Biol; 2016; 854():533-9. PubMed ID: 26427456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
    Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
    Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.
    Li Q; Miller R; Han PY; Pang J; Dinculescu A; Chiodo V; Hauswirth WW
    Mol Vis; 2008 Sep; 14():1760-9. PubMed ID: 18836574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Status of RPE65 Gene Therapy Trials: Safety and Efficacy.
    Pierce EA; Bennett J
    Cold Spring Harb Perspect Med; 2015 Jan; 5(9):a017285. PubMed ID: 25635059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year.
    Cideciyan AV; Hauswirth WW; Aleman TS; Kaushal S; Schwartz SB; Boye SL; Windsor EA; Conlon TJ; Sumaroka A; Pang JJ; Roman AJ; Byrne BJ; Jacobson SG
    Hum Gene Ther; 2009 Sep; 20(9):999-1004. PubMed ID: 19583479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.